Holen Sie sich die Stockscreener-App
3.175
1.92%
0.045
Alvotech Aktie (ALVO) Neueste Nachrichten
Alvotech stock hits new 52-week low on UBS price target cut to $6 amid biosimilar launch delays - AD HOC NEWS
Alvotech (NASDAQ:ALVO) Sets New 12-Month Low After Analyst Downgrade - MarketBeat
Alvotech price target lowered to $4 from $5 at Barclays - TipRanks
Alvotech Drops 14% Amid Prevailing Negative Market Sentiment - Bitget
Alvotech price target lowered to $4 from $8 at Deutsche Bank - TipRanks
Barclays Lowers Price Target for Alvotech (ALVO) to $4.00, Maint - GuruFocus
Alvotech Stock Hits Day Low of $3.44 Amid Price Pressure - Markets Mojo
UBS cuts Alvotech stock price target on delayed biosimilar launches - Investing.com UK
Alvotech (ALVO) Maintains 'Buy' Rating with Lowered Price Target by UBS | ALVO Stock News - GuruFocus
UBS Group Cuts Alvotech (NASDAQ:ALVO) Price Target to $6.00 - MarketBeat
Barclays Has Lowered Expectations for Alvotech (NASDAQ:ALVO) Stock Price - MarketBeat
UBS Adjusts Alvotech Price Target to $6 From $10, Maintains Buy Rating - marketscreener.com
Deutsche Bank Adjusts Alvotech Price Target to $4 From $8, Maintains Hold Rating - marketscreener.com
Alvotech: Regulatory Setbacks Priced In, Biosimilar Strength Supports Buy Rating Despite Lowered Target - TipRanks
Alvotech SA stock hits 52-week low at $3.42 amid challenging year - Investing.com Canada
Barclays lowers Alvotech stock price target to $4 on approval timing - Investing.com India
Barclays lowers Alvotech stock price target to $4 on approval timing By Investing.com - Investing.com South Africa
Alvotech (NASDAQ:ALVO) Trading Down 5.1%Here's What Happened - MarketBeat
Alvotech SA stock hits 52-week low at $3.42 amid challenging year By Investing.com - Investing.com South Africa
Northland Securities Weighs in on Alvotech FY2026 Earnings - MarketBeat
Operating cash flow per share of Alvotech – NASDAQ:ALVOW - TradingView
Free cash flow per share of Alvotech – NASDAQ:ALVOW - TradingView
Analyst Calls: Can Alvotech Equity Warrant maintain its current growth rateWeekly Market Summary & Growth Oriented Trading Recommendations - baoquankhu1.vn
Alvotech Stock Faces Market Cap Decline Amid Biotech Sector Pressures in Early 2026 - AD HOC NEWS
Alvotech (NASDAQ:ALVO) Upgraded by Zacks Research to Hold Rating - MarketBeat
Alvotech stock advances on biosimilar approvals and capacity expansion amid strong biotech momentum - AD HOC NEWS
Did Alvotech’s (ALVO) Profitability Turn and Expanding Biosimilar Pipeline Just Recast Its Investment Narrative? - Yahoo Finance
Alvotech Q4 2025 slides: 21% revenue growth amid FDA hurdles By Investing.com - Investing.com Canada
Alvotech (ALVO) TTM Profitability Challenged By Q4 US$108.5 Million Net Loss - simplywall.st
Alvotech outlines 2026 revenue target of $650M-$700M while expanding global biosimilar launches - MSN
Alvotech (NASDAQ:ALVO) Hits New 1-Year LowShould You Sell? - MarketBeat
Alvotech Q4 2025 slides: 21% revenue growth amid FDA hurdles - Investing.com
Earnings call transcript: Alvotech Q4 2025 Surpasses Earnings Forecast By Investing.com - Investing.com Australia
ALVO: 2025 revenue rose 21% to $593M; 2026 guidance set at $650–$700M with strong pipeline momentum - TradingView
Alvotech Q4 Earnings Call Highlights - MarketBeat
Earnings call transcript: Alvotech Q4 2025 Surpasses Earnings Forecast - Investing.com
Alvotech 2025 Q4ResultsEarnings Call Presentation (NASDAQ:ALVO) 2026-03-19 - Seeking Alpha
Alvotech Posts Strong 2025 Growth, Adds Approvals and New CEO as Biosimilar Pipeline Expands - TipRanks
Alvotech (NASDAQ: ALVO) turns profit as 2025 revenue rises 21% and sets 2026 growth targets - Stock Titan
Alvotech earnings beat by $0.11, revenue topped estimates - Investing.com India
Alvotech earnings beat by $0.11, revenue topped estimates By Investing.com - Investing.com South Africa
Alvotech Q4 Revenue Increases; 2026 Revenue Guidance Issued - marketscreener.com
Alvotech Provides Updates on Launch & Regulatory Plans for Golimumab, High Dose Aflibercept, Vedolizumab and Pembrolizumab Biosimilars - Pearce IP
Alvotech SA reports results for the quarter ended December 31Earnings Summary - TradingView
Alvotech (NASDAQ:ALVO) Reports Q4 Revenue Beat but Significant EPS Miss, Stock Falls on Weak Guidance - ChartMill
Alvotech's Guidance Hike Sets Higher Bar for 2026 Growth Execution - Bitget
ALVOTECH ($ALVO) Releases Q4 2025 Earnings - Quiver Quantitative
Alvotech Reports Strong Q4 2025 Financial Results and Provides Business Update on Biosimilar Developments - Quiver Quantitative
Alvotech Q4 2025 and Full Year 2025 Financial Results - Caledonian Record
Alvotech expects four U.S. biosimilar approvals by late 2026 - Stock Titan
Alvotech’s fourth quarter results need to support the bearish outlook in order to shift the prevailing story - Bitget
Earnings Scheduled For March 18, 2026 - Benzinga
Alvotech, Teva reach settlement and license agreement with Regeneron for AVT06 - MSN
Alvotech Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com
Alvotech's Q4 Report: Regulatory Concerns for AVT05 Diminish Impact of Revenue Outperformance - Bitget
Alvotech (ALVO) Q4 2025 Earnings Report Preview: What To Expect - GuruFocus
3.23%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):